BGLAP and diabetes mellitus: Second, TyG-BMI’s strong correlation with hepatic (ALT/AST) and bone turnover markers (e.g., osteocalcin, β-CrossLaps) highlights its potential as a surrogate endpoint in clinical trials evaluating novel therapies for diabetes-related extra-glycemic complications.